Yoshiro Tsukiyama
Kobe University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yoshiro Tsukiyama.
Journal of Cardiology | 2016
Amane Kozuki; Toshiro Shinke; Hiromasa Otake; Yoichi Kijima; Tomoya Masano; Ryoji Nagoshi; Kimitake Imamura; Ryudo Fujiwara; Hiroyuki Shibata; Ryo Takeshige; Yoshiro Tsukiyama; Kenichi Yanaka; Shinsuke Nakano; Yusuke Fukuyama; Seinosuke Kawashima; Ken-ichi Hirata; Junya Shite
BACKGROUND This study aimed to assess chronic-phase suppression of neointimal proliferation and arterial healing following paclitaxel-coated (PTX) and bare metal stent (BMS) implantation in the superficial femoral artery using optical coherence tomography (OCT). METHODS Twenty-five patients with 68 stents underwent an 8-month OCT follow-up. Besides standard OCT variables, neointimal characterization and frequencies of peri-strut low-intensity area (PLIA), macrophage accumulation, and in-stent thrombi were evaluated. RESULTS The mean neointimal thickness was significantly less with PTX stents (544.9±202.2 μm vs. 865.0±230.6 μm, p<0.0001). The covered and uncovered strut frequencies were significantly smaller and larger, respectively, in the PTX stent group vs. the BMS group (93.7% vs. 99.4%; p<0.0001, 4.0% vs. 0.4%; p<0.0001, respectively). Heterogeneous neointima was only observed in the PTX stent group (12.5% vs. 0%, p=0.017). The frequencies of PLIA and macrophage accumulation were significantly greater in the PTX stent group (87.2% vs. 67.6%, p=0.001 and 46% vs. 9.1%, p=0.003, respectively). CONCLUSION After 8 months, reduced neointimal proliferation was observed with PTX stent implantation. On the other hand, delayed arterial healing was observed compared with BMS.
Atherosclerosis | 2018
Hiroyuki Yamamoto; Naofumi Yoshida; Toshiro Shinke; Hiromasa Otake; Masaru Kuroda; Kazuhiko Sakaguchi; Yushi Hirota; Takayoshi Toba; Hachidai Takahashi; Daisuke Terashita; Kenzo Uzu; Natsuko Tahara; Yuto Shinkura; Kouji Kuroda; Yoshinori Nagasawa; Yuichiro Nagano; Yoshiro Tsukiyama; Kenichi Yanaka; Takuo Emoto; Naoto Sasaki; Tomoya Yamashita; Wataru Ogawa; Ken-ichi Hirata
BACKGROUND AND AIMS This study examined the impact of CD14++CD16+ monocytes on coronary plaque vulnerability, as assessed by optical coherence tomography (OCT), and investigated their association with daily glucose fluctuation. Although increased CD14++CD16+ monocyte levels have been reported to increase cardiovascular events, their impact on coronary plaque vulnerability in coronary artery disease (CAD) patients with or without diabetes mellitus (DM) remains unclear. METHODS This prospective observational study included 50 consecutive patients with CAD, receiving lipid-lowering therapy and undergoing coronary angiography and OCT. Patients were divided into 3 tertiles according to the CD14++CD16+ monocyte percentages assessed by flow cytometry. Standard OCT parameters were assessed for 97 angiographically intermediate lesions (diameter stenosis: 30-70%). Daily glucose fluctuation was analyzed by measuring the mean amplitude of glycemic excursion (MAGE). RESULTS CD14++CD16+ monocytes negatively correlated with fibrous cap thickness (r = -0.508, p < 0.01). The presence of thin-cap fibroatheroma (TCFA) was increased stepwise according to the tertile of CD14++CD16+ monocytes (0 [tertile 1] vs. 5 [tertile 2] vs. 10 [tertile 3], p < 0.01). CD14++CD16+ monocytes were a significant determinant of TCFA (OR 1.279, p = 0.001). In non-DM patients, a significant relationship was found between CD14++CD16+ monocytes and MAGE (r = 0.477, p = 0.018). CONCLUSIONS CD14++CD16+ monocytes were associated with coronary plaque vulnerability in CAD patients with well-regulated lipid levels both in DM and non-DM patients. Cross-talk between glucose fluctuation and CD14++CD16+ monocytes may enhance plaque vulnerability, particularly in non-DM patients. CD14++CD16+ monocytes could be a possible therapeutic target for coronary plaque stabilization.
Journal of Cardiology | 2018
Yoshiro Tsukiyama; Amane Kozuki; Toshiro Shinke; Hiromasa Otake; Yoichi Kijima; Tomoya Masano; Ryoji Nagoshi; Hiroyuki Shibata; Ryo Takeshige; Kenichi Yanaka; Junya Shite; Ken-ichi Hirata
BACKGROUND Recent studies suggested protruding thrombus and atheroma after stent placement could be a substrate for subsequent adverse ischemic events. Although protruded atherothrombotic burden can be assessed as intra-stent tissue (IST) by optical coherence tomography (OCT), the effects of potent antiplatelet therapy on the acute phase resolution of IST in patients with acute coronary syndrome (ACS) was unknown. METHODS Ninety-six consecutive ACS patients with multi-vessel disease were enrolled in this prospective registry. In combination with aspirin, either clopidogrel or prasugrel was selected according to the date of enrolment. OCT examination was done immediately after percutaneous coronary intervention (post-PCI) and 10 days after index PCI (follow-up acute phase) to calculate averaged IST score as semi-quantitative measures of IST. High residual platelet reactivity (HRPR) was defined as platelet reactivity units (PRU)≥240 by VerifyNow P2Y12 assay (Accumetrics Inc., San Diego, CA, USA). RESULTS Thirty two patients (38 stents) were enrolled in the prasugrel group and sixty four patients (72 stents) in the clopidogrel group. Averaged IST scores post-PCI were similar between the two groups (0.68±0.41 vs. 0.68±0.40, p=0.99), which decreased in all of the prasugrel group and in 87.5% of the clopidogrel group (p=0.02). Consequently, changes in averaged IST score (delta averaged IST score) were significantly greater in the prasugrel group compared to those in the clopidogrel group (-0.411±0.288 vs. -0.299±0.270, p=0.045). The frequency of HRPR was significantly lower in the prasugrel group (10.0% vs 32.4%, p=0.028). CONCLUSIONS Prasugrel plus aspirin achieved greater acute phase reduction of IST than clopidogrel plus aspirin, which might underlie the clinical benefit of potent antiplatelet therapy in ACS. (UMIN000018751).
Data in Brief | 2018
Hiroyuki Yamamoto; Naofumi Yoshida; Toshiro Shinke; Hiromasa Otake; Masaru Kuroda; Kazuhiko Sakaguchi; Yushi Hirota; Takayoshi Toba; Hachidai Takahashi; Daisuke Terashita; Kenzo Uzu; Natsuko Tahara; Yuto Shinkura; Kouji Kuroda; Yoshinori Nagasawa; Yuichiro Nagano; Yoshiro Tsukiyama; Kenichi Yanaka; Takuo Emoto; Naoto Sasaki; Tomoya Yamashita; Wataru Ogawa; Ken-ichi Hirata
Data presented in this article are supplementary material to our research article entitled “Impact of CD14++CD16+ monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients” [1]. This article contains the data of study population, diagnostic ability of CD14++CD16+ monocytes to identify thin-cap fibroatheromas, and association between laboratory variables and plaque properties.
Journal of the American College of Cardiology | 2016
Yuichiro Nagano; Hiromasa Otake; Amane Harada; Katsuhiro Murakami; Maria Kiriyama; Yasuhiro Irino; Takayoshi Toba; Hachidai Takahashi; Daisuke Terashita; Koji Kuroda; Kenzo Uzu; Natsuko Tahara; Yuto Shinkura; Yoshinori Nagasawa; Yoshiro Tsukiyama; Kenichi Yanaka; Hiroyuki Yamamoto; Toshiro Shinke; Tatsuro Ishida; Ryuji Toh; Ken-ichi Hirata
The importance of HDL functionality on coronary artery disease has been repeatedly demonstrated in recent studies. However, the association between HDL functionality and stent failure has yet to be clarified. Recently, we established a cell-free assay system to evaluate the capacity of HDL to accept
Journal of the American College of Cardiology | 2016
Takayuki Ishihara; Osamu Iida; Amane Kozuki; Toshiro Shinke; Masashi Fukunaga; Tetsuo Horimatsu; Kenichi Fujii; Junya Shite; Daisuke Terashita; Yoshiro Tsukiyama; Kan Zen; Mitsuyoshi Takahara; Masaaki Uematsu; Shinsuke Nanto
METHODS From January 2008 to May 2015, a total of 226 consecutive patients with 250 wounds underwent complete angiosome-targeted PTA for only ischemic foot wound and multi-vessel BTK artery disease. We evaluated the clinical outcome of angiosome-targeted single-vessel versus multi-vessel PTA. The primary endpoint was defined as the complete wound healing within 12 months without death before wound healing, unexpected amputation or flap or target vessel revascularization, or death. The secondary endpoint of the study was the major adverse limb event (MALE) at 1 year.
Journal of the American College of Cardiology | 2016
Hiroyuki Yamamoto; Toshiro Shinke; Hiromasa Otake; Tomofumi Takaya; Masaru Kuroda; Takayoshi Toba; Hachidai Takahashi; Daisuke Terashita; Kenzo Uzu; Koji Kuroda; Natsuko Tahara; Daiji Kashiwagi; Yoshinori Nagasawa; Yoshiro Tsukiyama; Kenichi Yanaka; Ken-ichi Hirata
Left ventricular systolic or diastolic dysfunction may lead to elevation in pulmonary capillary wedge pressure (PCWP) during pre-balloon testing at atrial septal defect (ASD) closure, through abrupt closure of left to right shunt. However, the association between acute hemodynamic changes and
Journal of the American College of Cardiology | 2016
Yuto Shinkura; Kazuhiko Nakayama; Takayoshi Toba; Hachidai Takahashi; Daisuke Terashita; Kenzo Uzu; Koji Kuroda; Natsuko Tahara; Yoshinori Nagasawa; Yuichiro Nagano; Hiroyuki Yamamoto; Yoshiro Tsukiyama; Kenichi Yanaka; Naoki Tamada; Hiromasa Otake; Toshiro Shinke; Noriaki Emoto; Ken-ichi Hirata
Hospital, kobe city, Japan; Kobe University, Kobe, Japan; Wakayama Medical University; Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York; Aichi Medical University, Kobe-shi, Japan; Federal University of São Paulo; Morehouse College; American Heart of Poland; Tufts Medical Center, Kobe, Japan; Center for Cardiovascular Research and Development, American Heart of Poland Inc
Journal of the American College of Cardiology | 2016
Toshiro Shinke; Amane Kozuki; Osamu Iida; Takayuki Ishihara; Kan Zen; Masashi Fukunaga; Tetsuo Horimatsu; Kenichi Fujii; Junya Shite; Daisuke Terashita; Yoshiro Tsukiyama; Mitsuyoshi Takahara; Masaaki Uematsu; Shinsuke Nanto
Durable long-term effectiveness with paclitaxel-eluting stent (Zilver PTX stent) in superficial femoral artery (SFA) lesion over standard endovascular therapy has been demonstrated. However, delayed vascular healing which may lead to rare but serious adverse event of late stent thrombosis remains a
Journal of Interventional Cardiac Electrophysiology | 2016
Ryudo Fujiwara; Kimitake Imamura; Yoichi Kijima; Tomoya Masano; Ryoji Nagoshi; Amane Kohzuki; Hiroyuki Shibata; Yoshiro Tsukiyama; Ryo Takeshige; Kenichi Yanaka; Shinsuke Nakano; Yusuke Fukuyama; Junya Shite